Research
Hormonal
Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.
If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.
StrongSupportsHIGH confidence
Рандомизированное клиническое исследование SURMOUNT-1 показало, что применение тирзепатида у пациентов с ИзМТ и ожирением без СД 2 типа вызывает значительную дозозависимую потерю массы тела (-15,0% ... при еженедельных дозах тирзепатида 5 мг, -19,5% ... при дозах 10 мг и -20,9% ... при дозах 15 мг).
Why this rating
Based on a cited randomized clinical trial (SURMOUNT-1) and meta-analyses.
Source
Overweight and obesity in metabolic syndrome
С. В. Недогода et al. · Russian Journal of Cardiology · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →